BCRT

BioCryst is a commercial-stage rare disease biotechnology company focused on discovering, developing, and commercializing oral small-molecule and protein therapeutics. The company is best known for ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor approved for prophylaxis of hereditary angioedema, and it also has legacy influenza product RAPIVAB/peramivir. Its current pipeline includes navenibart for hereditary angioedema, BCX17725 for Netherton syndrome, avoralstat for diabetic macular edema, and STAR-0310 for atopic dermatitis. BioCryst emphasizes structure-guided drug design and has operations centered in Durham, North Carolina, with discovery roots in Birmingham, Alabama. The requested name "BCRT" does not exactly match the company; the best-supported healthcare company match is BioCryst, whose public ticker is "BCRX".